Principia Biopharma Inc. (PRNB): Price and Financial Metrics


Principia Biopharma Inc. (PRNB)

Today's Latest Price: $63.13 USD

5.82 (10.16%)

Updated Jan 17 12:00am

Add PRNB to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

PRNB Stock Summary

  • Principia Biopharma Inc's stock had its IPO on September 14, 2018, making it an older stock than just 1.48% of US equities in our set.
  • The ratio of debt to operating expenses for Principia Biopharma Inc is higher than it is for about merely 0.37% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Principia Biopharma Inc is reporting a growth rate of 770.31%; that's higher than 98.17% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Principia Biopharma Inc, a group of peers worth examining would be ACIU, MGNX, PIRS, ARGX, and CTMX.
  • Visit PRNB's SEC page to see the company's official filings. To visit the company's web site, go to www.principiabio.com.
PRNB Daily Price Range
PRNB 52-Week Price Range

PRNB Stock Price Chart More Charts


PRNB Price/Volume Stats

Current price $63.13 52-week high $64.25
Prev. close $57.31 52-week low $25.35
Day low $57.19 Volume 692,200
Day high $64.24 Avg. volume 344,667
50-day MA $44.93 Dividend yield N/A
200-day MA $36.31 Market Cap 2.07B

Principia Biopharma Inc. (PRNB) Company Bio


Principia Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has collaboration agreements with Genzyme Corporation and AbbVie Biotechnology Limited. Principia Biopharma Inc. was founded in 2008 and is based in South San Francisco, California.





PRNB Latest News Stream


Event/Time News Detail
Loading, please wait...

PRNB Latest Social Stream


Loading social stream, please wait...

View Full PRNB Social Stream

PRNB Price Returns

1-mo 6.55%
3-mo 102.79%
6-mo 61.71%
1-year 96.79%
3-year N/A
5-year N/A
YTD 15.24%
2019 100.00%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5404 seconds.